Biotech companies can't afford to be surprised by regulatory changes mid-program. RegNexia AI keeps your team informed on every pathway update, guidance revision, and market entry requirement — automatically.
50+
Global authorities tracked
4
Continents of coverage
24/7
Continuous monitoring
AI
Powered analysis
Challenges
Regulatory pathways for novel therapies change faster than teams can track
Automated monitoring of breakthrough therapy, fast-track, accelerated approval, and PRIME designation guidance keeps development teams current without manual effort.
Small teams can't afford dedicated regulatory intelligence staff
RegNexia AI acts as a continuous intelligence layer — delivering summarized, actionable updates without requiring headcount to staff the monitoring function.
Global market entry requires understanding dozens of different regulatory landscapes
A unified dashboard covers 50+ authorities simultaneously, giving biotech companies multi-market visibility regardless of how lean the regulatory team is.
Missing a guideline update can derail a program or delay a filing
Smart watchlists by therapeutic area, modality, and market ensure every relevant guidance change reaches the right person before deadlines are impacted.
Capabilities
Track FDA Breakthrough Therapy, Fast Track, Accelerated Approval, and EMA PRIME scheme guidance changes as they happen — critical for innovative therapy programs.
Monitor FDA ODD, EMA Orphan Designation, and rare disease regulatory frameworks across all jurisdictions where you plan to seek designation.
Track evolving FDA CBER guidance, EMA CAT opinions, and global advanced therapy regulatory frameworks for ATMPs, gene therapies, and cell-based treatments.
Stay ahead of IND-enabling regulatory changes, IMPD requirements, protocol amendment standards, and clinical trial regulation updates across key markets.
Build your market entry strategy on current intelligence. Monitor NDA, BLA, MAA, and regional submission pathway requirements in your target markets.
Create watchlists by therapeutic modality — biologics, small molecules, mRNA, CAR-T, gene editing — so updates are always contextualized to your pipeline.
Pipeline Coverage
Discovery & Early Development
Monitor regulatory science policies, preclinical guidance, and early-phase clinical trial requirements. Understand what regulators expect before you file your IND.
Clinical Development
Track protocol design expectations, adaptive trial guidance, patient enrichment strategies, and PRO endpoint requirements across FDA, EMA, and other ICH markets.
Pre-BLA / Pre-MAA
Monitor rolling submission guidance, priority review criteria, and submission format requirements so your team is aligned with current regulator expectations at filing.
Market Access & Post-Approval
Stay current on lifecycle management guidance, label expansion requirements, post-marketing commitment standards, and pharmacovigilance obligations after approval.
Therapeutic Areas
Set watchlists by therapeutic area and modality so your monitoring is laser-focused on what matters to your pipeline.
Regulators
From CBER and CDER to EMA's CAT and CHMP — monitor the bodies that determine your pathway forward.